Chemotherapy for Muscle-Invasive Bladder Cancer
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 17, Issue 1, Pages -Publisher
SPRINGER
Keywords
Categories
Ask authors/readers for more resources
Authors
I am an author on this paper
Reviews
Recommended
Extranodal Extension Predicts Poor Survival Outcomes among Patients with Bladder Cancer
Yi-An Liao, Chun-Ju Chiang, Wen-Chung Lee, Bo-Zhi Zhuang, Chung-Hsin Chen, Yeong-Shiau Pu
CANCERS (2021)
Validating a nodal regression system for gastric cancer: An ancillary cohort study of the GASTRODOC trial
Luca Saragoni, Leonardo Solaini, Daniele Marrelli, Maria Raffaella Ambrosio, Maria Bencivenga, Anna Tomezzoli, Carlo Milandri, Valentina Terrinazzi, Gian Luca Baiocchi, Carla Baronchelli, Flavia Foca, Giorgio Ercolani, Paolo Morgagni
INTERNATIONAL JOURNAL OF SURGERY (2021)
Neoadjuvant versus adjuvant chemotherapy in bladder cancer: a nationwide cohort study
Se Young Choi, Moon Soo Ha, Byung Hoon Chi, Jin Wook Kim, In Ho Chang, Tae-Hyoung Kim, Soon Chul Myung, Myoungsuk Kim, Kyung-Eun Lee, Yuwon Kim, Hyun-Ki Woo, Dae-Sung Kyoung, Hasung Kim
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)
Singe intraoperative instillation of chemotherapy during radical cystectomy for bladder cancer: Oncological outcome and survival predictors
Jingtian Yang, Kaiwen Li, Yishan Zhang, Jintao Hu, Hao Liu, Wen Dong, Hai Huang, Tianxin Lin, Jian Huang, Wang He
CANCER MEDICINE (2023)
Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine
Shigehiro Tsukahara, Masaki Shiota, Dai Takamatsu, Shohei Nagakawa, Takashi Matsumoto, Ryo Kiyokoba, Mikako Yagi, Daiki Setoyama, Nozomi Noda, Shinya Matsumoto, Tetsutaro Hayashi, Alberto Contreras-Sanz, Peter C. Black, Junichi Inokuchi, Kenichi Kohashi, Yoshinao Oda, Takeshi Uchiumi, Masatoshi Eto, Dongchon Kang
SCIENTIFIC REPORTS (2022)
Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
Chengyu You, Xianhui Li, Yuelin Du, Hui Wang, Xiaojun Zhang, Tangqiang Wei, Anguo Wang
PEERJ (2021)
Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer
Joanne Kotsopoulos, Neda Zamani, Barry Rosen, John R. McLaughlin, Harvey A. Risch, Shana J. Kim, Ping Sun, Mohammad Reza Akbari, Steven A. Narod
BRITISH JOURNAL OF CANCER (2022)
Disruption of the Gut Microbiota Confers Cisplatin Resistance in Epithelial Ovarian Cancer
Laura M. Chambers, Emily L. Esakov Rhoades, Rashmi Bharti, Chad Braley, Surabhi Tewari, Lexie Trestan, Zahraa Alali, Defne Bayik, Justin D. Lathia, Naseer Sangwan, Peter Bazeley, Amy S. Joehlin-Price, Zeneng Wang, Sumita Dutta, Mohammed Dwidar, Adeline Hajjar, Philip P. Ahern, Jan Claesen, Peter Rose, Roberto Vargas, J. Mark Brown, Chad M. Michener, Ofer Reizes
CANCER RESEARCH (2022)
Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases
Preeti Kanikarla Marie, Cara Haymaker, Edwin Roger Parra, Young Uk Kim, Rossana Lazcano, Swati Gite, Daniele Lorenzini, Ignacio I. Wistuba, Rebecca S. Slack Tidwell, Xiaofei Song, Wai Chin Foo, Dipen M. Maru, Yun Shin Chun, Andy Futreal, Bryan Kee, David Menter, Luisa Solis, Ching-Wei Tzeng, Christine Parseghian, Kanwal Raghav, Van Morris, Chia-Chi Chang, Robert Jenq, Alda Tam, Chantale Bernatchez, Scott Kopetz, Jean-Nicolas Vauthey, Michael J. Overman
CLINICAL CANCER RESEARCH (2021)
Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer
Judit Borcsok, Miklos Diossy, Zsofia Sztupinszki, Aurel Prosz, Viktoria Tisza, Sandor Spisak, Orsolya Rusz, Dag R. Stormoen, Helle Pappot, Istvan Csabai, Soren Brunak, Kent W. Mouw, Zoltan Szallasi
CLINICAL CANCER RESEARCH (2021)
Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs
Zhonglin Hao, Saurabh Parasramka, Quan Chen, Aasems Jacob, Bin Huang, Timothy Mullett, Al B. Benson
ONCOLOGIST (2023)
Survival after Multimodal Treatment Including Surgery for Metastatic Esophageal Cancer: A Systematic Review
Thomas Bardol, Lorenzo Ferre, Safa Aouinti, Marie Dupuy, Eric Assenat, Jean-Michel Fabre, Marie-Christine Picot, Regis Souche
CANCERS (2022)
Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition
Philip Baum, Samantha Taber, Stella Erdmann, Thomas Muley, Mark Kriegsmann, Petros Christopoulos, Michael Thomas, Hauke Winter, Joachim Pfannschmidt, Martin E. Eichhorn
CANCERS (2021)
Selection of Treatment Regimens for Recurrent Cervical Cancer
Xiaopei Chao, Xiaochen Song, Huanwen Wu, Yan You, Ming Wu, Lei Li
FRONTIERS IN ONCOLOGY (2021)
Predictors of Survival in Elderly Patients with Metastatic Colon Cancer: A Population-Based Cohort Study
Bogdan Badic, Anne-Marie Bouvier, Veronique Bouvier, Marie Morvan, Valerie Jooste, Arnaud Alves, Jean-Baptiste Nousbaum, Noemi Reboux
CANCERS (2022)
An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A).
Guru Sonpavde, Aurelien Marabelle, Yohann Loriot, Cora N. Sternberg, Jae-Lyun Lee, Aude Flechon, Guilhem Roubaud, Damien Pouessel, Vittorina Zagonel, Fabio Calabro, Giuseppe L. Banna, Sang Joon Shin, Vera Francisco Emilio Badillo, Thomas Powles, Eva Hellmis, Paulo Andre Palhares de Miranda, Ana Rita Lima, William Sawyer, Sebastien J. Hotte
JOURNAL OF CLINICAL ONCOLOGY (2021)
A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
Karim Fizazi, Xavier Maldonado, Stephanie Foulon, Guilhem Roubaud, Raymond S. McDermott, Aude Flechon, Bertrand F. Tombal, Stephane Supiot, Dominik R. Berthold, Philippe Ronchin, Gabriel Kacso, Gwenaelle Gravis, Fabio Calabro, Jean Francois Berdah, Ali Hasbini, Marlon Silva, Antoine Thiery-Vuillemin, Isabelle Rieger, Marie Laure Tanguy, Alberto Bossi
JOURNAL OF CLINICAL ONCOLOGY (2021)
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort
G. Fornarini, S. E. Rebuzzi, G. L. Banna, F. Calabro, G. Scandurra, U. De Giorgi, C. Masini, C. Baldessari, E. Naglieri, C. Caserta, S. Manacorda, M. Maruzzo, M. Milella, C. Buttigliero, R. Tambaro, P. Ermacora, F. Morelli, F. Nole, C. Astolfi, C. N. Sternberg
ESMO OPEN (2021)
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy
A. Bamias, A. S. Merseburger, Y. Loriot, N. James, E. Choy, D. Castellano, F. Lopez-Rios, F. Calabro, M. Kramer, G. de Velasco, R. Zakopoulou, K. Tzannis, C. N. Sternberg
ESMO OPEN (2021)
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study
Daniele Raggi, Patrizia Giannatempo, Laura Marandino, Francesco Pierantoni, Marco Maruzzo, Helga Lipari, Giuseppe L. Banna, Ugo De Giorgi, Chiara Casadei, Emanuele Naglieri, Sebastiano Buti, Melissa Bersanelli, Marco Stellato, Daniele Santini, Francesca Vignani, Giandomenico Roviello, Antonello Veccia, Orazio Caffo, Tania Losanno, Fabrizio Calabro, Claudia Mucciarini, Sandro Pignata, Andrea Necchi, Massimo Di Maio
CLINICAL GENITOURINARY CANCER (2022)
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Matthew R. Smith, Maha Hussain, Fred Saad, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Evgeny Kopyltsov, Chandler H. Park, Boris Alekseev, Alvaro Montesa-Pino, Dingwei Ye, Francis Parnis, Felipe Cruz, Teuvo L. J. Tammela, Hiroyoshi Suzuki, Tapio Utriainen, Cheng Fu, Motohide Uemura, Maria J. Mendez-Vidal, Benjamin L. Maughan, Heikki Joensuu, Silke Thiele, Rui Li, Iris Kuss, Bertrand Tombal
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
Guru P. Sonpavde, Cora N. Sternberg, Yohann Loriot, Aurelien Marabelle, Jae Lyun Lee, Aude Flechon, Guilhem Roubaud, Damien Pouessel, Vittorina Zagonel, Fabio Calabro, Giuseppe L. Banna, Sang Joon Shin, Francisco E. Vera-Badillo, Thomas Powles, Eva Hellmis, Paulo A. P. Miranda, Ana Rita Lima, Ugochi Emeribe, Sun Min Oh, Sebastien J. Hotte
EUROPEAN JOURNAL OF CANCER (2022)
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design
Karim Fizazi, Stephanie Foulon, Joan Carles, Guilhem Roubaud, Ray McDermott, Aude Flechon, Bertrand Tombal, Stephane Supiot, Dominik Berthold, Philippe Ronchin, Gabriel Kacso, Gwenaelle Gravis, Fabio Calabro, Jean-Francois Berdah, Ali Hasbini, Marlon Silva, Antoine Thiery-Vuillemin, Igor Latorzeff, Loic Mourey, Brigitte Laguerre, Sophie Abadie-Lacourtoisie, Etienne Martin, Claude El Kouri, Anne Escande, Alvar Rosello, Nicolas Magne, Friederike Schlurmann, Frank Priou, Marie-Eve Chand-Fouche, Salvador Villa Freixa, Muhammad Jamaluddin, Isabelle Rieger, Alberto Bossi
LANCET (2022)
Cultural adaptation of the Italian version o the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)
Caterina Caminiti, Jane Bryce, Silvia Riva, Diane Ng, Francesca Diodati, Elisa Iezzi, Lucia Sparavigna, Silvia Novello, Camillo Porta, Lucia Del Mastro, Giuseppe Procopio, Saverio Cinieri, Amalia Falzetta, Fabio Calabro, Vito Lorusso, Alessio Aligi Cogoni, Giampaolo Tortora, Marco Maruzzo, Rodolfo Passalacqua, Francesco Cognetti, Vincenzo Adamo, Enrica Capelletto, Alessandra Ferrari, Michela Bagnalasta, Maurizio Bassi, Annalisa Nicelli, Davide De Persis, Alessia D'Acunti, Elisabetta Iannelli, Francesco Perrone, Sandra A. Mitchell
TUMORI JOURNAL (2023)
Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment
Cora N. Sternberg, Nara Shin, Konstantin Chernyshov, Fabio Calabro, Linda Cerbone, Giuseppe Procopio, Natalia Miheecheva, Georgy Sagaradze, Alisa Zaichikova, Naira Samarina, Alexandra Boyko, Jessica H. Brown, Leysan Yunusova, Daniela Guevara, Jyothi Manohar, Michael Sigouros, Majd Al Assaad, Olivier Elemento, Juan Miguel Mosquera
FRONTIERS IN ONCOLOGY (2022)
The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort
Mariaconsiglia Ferriero, Francesco Prata, Riccardo Mastroianni, Cosimo De Nunzio, Giorgia Tema, Gabriele Tuderti, Alfredo Maria Bove, Umberto Anceschi, Aldo Brassetti, Leonardo Misuraca, Silvana Giacinti, Fabio Calabro, Salvatore Guaglianone, Andrea Tubaro, Rocco Papalia, Costantino Leonardo, Michele Gallucci, Giuseppe Simone
PROSTATE CANCER AND PROSTATIC DISEASES (2022)
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
Aristotelis Bamias, Axel Merseburger, Yohann Loriot, Nicholas James, Ernest Choy, Daniel Castellano, F. Lopez-Rios, Fabio Calabro, Mario Kramer, Guillermo de Velasco, Roubini Zakopoulou, Kimon Tzannis, Cora N. Sternberg
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
S. E. Rebuzzi, A. Signori, S. Buti, G. L. Banna, V Murianni, A. Damassi, M. Maruzzo, D. Giannarelli, G. Tortora, L. Galli, M. Rizzo, U. De Giorgi, L. Antonuzzo, S. Bracarda, G. Carteni, F. Atzori, S. Tamberi, G. Procopio, L. Fratino, G. Lo Re, M. Santoni, C. Baldessari, A. Astone, F. Calabro, M. Brunelli, C. Porta, P. Rescigno, U. Basso, G. Fornarini
ESMO OPEN (2022)
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni, Francesco Massari, Zin W. Myint, Roberto Iacovelli, Martin Pichler, Umberto Basso, Jindrich Kopecky, Jakub Kucharz, Sebastiano Buti, Mimma Rizzo, Luca Galli, Thomas Buettner, Ugo De Giorgi, Ravindran Kanesvaran, Ondrej Fiala, Enrique Grande, Paolo Andrea Zucali, Giuseppe Fornarini, Maria T. Bourlon, Sarah Scagliarini, Javier Molina-Cerrillo, Gaetano Aurilio, Marc R. Matrana, Renate Pichler, Carlo Cattrini, Tomas Buechler, Emmanuel Seront, Fabio Calabro, Alvaro Pinto, Rossana Berardi, Anca Zgura, Giulia Mammone, Jawaher Ansari, Francesco Atzori, Rita Chiari, Aristotelis Bamias, Orazio Caffo, Giuseppe Procopio, Maria Bassanelli, Sara Merler, Carlo Messina, Zsofia Kueronya, Alessandra Mosca, Dipen Bhuva, Nuno Vau, Lorena Incorvaia, Sara Elena Rebuzzi, Giandomenico Roviello, Ignacio Ortego Zabalza, Alessandro Rizzo, Veronica Mollica, Giulia Sorgentoni, Fernando Sabino M. Monteiro, Rodolfo Montironi, Nicola Battelli, Camillo Porta
TARGETED ONCOLOGY (2023)
THE IMPACT OF LOCOREGIONAL TREATMENTS FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER ON DISEASE PROGRESSION: REAL LIFE EXPERIENCE FROM A MULTICENTER COHORT
Mariaconsiglia Ferriero, Gabriele Tuderti, Umberto Anceschi, Alfredo Maria Bove, Aldo Brassetti, Leonardo Misuraca, Salvatore Guaglianone, Riccardo Mastroianni, Cosimo De Nunzio, Silvana Giacinti, Giorgia Tema, Luca Cindolo, Andrea Tubaro, Michele Gallucci, Luigi Schips, Fabio Calabro, Giuseppe Simone
JOURNAL OF UROLOGY (2022)